Pharmacokinetics and pharmacodynamics of paxalisib in newly diagnosed glioblastoma patients with unmethylated MGMT promoter status: Final phase II study results

被引：1

作者：

Wen, P. ^{[1
]}

De Groot, J. F. ^{[2
]}

Battiste, J. ^{[3
]}

Goldlust, S. ^{[4
]}

Damek, D. ^{[5
]}

Ellingson, B. ^{[6
]}

Garner, J. ^{[7
]}

Friend, J. ^{[7
]}

Simpson, J. ^{[7
]}

Olivero, A. ^{[8
]}

Cloughesy, T. ^{[9
]}

机构：

[1] Dana Farber Canc Inst, Ctr Neuro Oncol, Boston, MA USA

[2] Univ Texas MD Anderson Canc Ctr, Neuro Oncol Dept, Houston, TX USA

[3] Univ Oklahoma, Neuro Oncol Dept, Stephenson Canc Ctr, Oklahoma City, OK USA

[4] Hackensack Univ, John Theurer Canc Ctr, Neuro Oncol Dept, Med Ctr, Hackensack, NJ USA

[5] Univ Colorado, UCHealth Canc Care, Neuro Oncol Dept, Canc Ctr, Anschutz Med Campus, Aurora, CO USA

[6] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Comp Vision & Imaging Biomarkers, Dept Radiol Sci,UCLA Brain Tumor Imaging Lab, Los Angeles, CA USA

[7] Kazia Therapeut Ltd, Clin Res, Sydney, NSW, Australia

[8] Olivero Consulting, Clin Res, Half Moon Bay, CA USA

[9] Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, Dept Neurol, Los Angeles, CA USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.414

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

280O

引用

页码：S667 / S667

页数：1